The George Washington University Medical Faculty Associates
Welcome,         Profile    Billing    Logout  
 15 Trials 
34 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fried, Linda
COPE-AKI, NCT05805709: A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the Trial

Recruiting
N/A
2145
US
Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education
University of Pittsburgh, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Kidney Injury
06/26
03/27
Simon, Gary
NCT01056185: Respiratory Virus Hospitalization Study (FLU 003 Plus)

Completed
N/A
1000
Europe, US, RoW
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Clinical & Translational Science Institute, University of Minnesota
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
08/24
08/24
Gomberg-Maitland, Mardi
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Terminated
3
186
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
08/24
08/24
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
RECAPTURE, NCT04882774: Telemonitoring to Treat Group 2 Pulmonary Hypertension

Withdrawn
2
30
US
Treprostinil Diolamine
Mardi Gomberg -Maitland MD, MSc, Ohio State University, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Pulmonary Hypertension Due to Left Heart Disease
04/25
04/27
Sen, Sabyasachi
NCT04126603: Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

Completed
4
38
US
Semaglutide, Placebos
Sabyasachi Sen
Diabetes Mellitus, Type 2
10/23
10/23
NDKD, NCT06110130: Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With

Recruiting
4
60
US
Empagliflozin 10 MG, Placebo
Washington D.C. Veterans Affairs Medical Center, Boehringer Ingelheim
Chronic Kidney Diseases
12/25
12/26
Rothschild, Richard
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
Awal, Hassan
NCT04126603: Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

Completed
4
38
US
Semaglutide, Placebos
Sabyasachi Sen
Diabetes Mellitus, Type 2
10/23
10/23
Hamed, Amen
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
I-SPY_COVID, NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Recruiting
2
1500
US
Remdesivir, GS-5734, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Firazyr, Apremilast, Otezla, dornase alfa, Pulmozyme, Celecoxib, celebrex, Famotidine, Pepcid, IC14, Aviptadil, Zyesami, narsoplimab, OMS721, Cyproheptadine, periactin, Cyclosporine, CsA
QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, University of California, Davis, Hoag Memorial Hospital Presbyterian, Main Line Health, DHR Health Institute for Research and Development, University of California, Irvine, Corewell Health, Kaiser Permanente, University of Michigan, West Virginia University, University of Miami, University Hospitals Cleveland Medical Center, Virtua Health, M.D. Anderson Cancer Center
COVID-19
07/28
07/30
NCT05495243: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Completed
2
40
US
ARINA-1, Placebo
Renovion, Inc.
Non-cystic Fibrosis Bronchiectasis
02/24
02/24
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
PTK0796-NTM-20203, NCT04922554: Oral Omadacycline Vs. Placebo in Adults with NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Completed
2
66
US
Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets
Paratek Pharmaceuticals Inc
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
06/24
07/24
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
Prasad, Poonam
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
Panjrath, Gurusher
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
Porterfield, Christopher
PACES, NCT04045665 / 2021-005022-18: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting
3
3200
Europe, Canada, US
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center
Atrial Fibrillation, Stroke, Bleeding
08/26
08/26
NCT04088071: Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation

Recruiting
N/A
15000
US
Catheter ablation
Heart Rhythm Clinical and Research Solutions, LLC, Biosense Webster, Inc.
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
12/27
12/27
NCT05860348: Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence

Recruiting
N/A
150
US
Barostim™ System
CVRx, Inc.
Heart Failure
05/28
05/28
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
NCT05839873: Abbott Ventricular Tachycardia PAS

Recruiting
N/A
150
US
FlexAbility SE Ablation Catheter
Abbott Medical Devices
Ventricular Tachycardia
08/28
11/28
Quinones, Ana
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
NCT02922764: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Checkmark From a trial for solid tumors
Jun 2020 - Jun 2020: From a trial for solid tumors
Active, not recruiting
1
146
US
RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
Inspirna, Inc.
Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
12/24
12/24
Sidahmed, Alfateh
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Active, not recruiting
3
608
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
REACT-AF, NCT05836987: The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Recruiting
3
5350
US
AFSW Guided DOAC, Apple Watch, Continuous DOAC therapy, Oral Anticoagulation therapy
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI)
Atrial Fibrillation
07/29
07/29
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
Huynh, Bao-An
CLEER, NCT05639933: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Recruiting
2
152
US
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Hoth Therapeutics, Inc., Worldwide Clinical Trials
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
06/25
06/25
KEYNOTE-A31, NCT04130542: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Active, not recruiting
1
276
US
LVGN6051, KEYTRUDA® (pembrolizumab)
Lyvgen Biopharma Holdings Limited, Merck Sharp & Dohme LLC
Cancer
12/25
12/25
Smith, Janellen
CLEER, NCT05639933: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Recruiting
2
152
US
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Hoth Therapeutics, Inc., Worldwide Clinical Trials
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
06/25
06/25

Download Options